Fr. 249.00

Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer

English · Hardback

Shipping usually within 1 to 3 weeks (not available at short notice)

Description

Read more

Informationen zum Autor RAYMOND M. REILLY is a Professor in the Leslie Dan Faculty of Pharmacy at the University of Toronto. He has more than twenty years of experience in the field of radiolabeled antibody and peptide targeting of cancer. Dr. Reilly has written over 180 publications in the field, including more than 100 scientific papers on radiopharmaceuticals for cancer imaging and targeted radiotherapy. Klappentext The essential, up-to-date guide to fighting cancer with targeted radiotherapyContinuing to gain momentum as a novel treatment strategy, targeted radiotherapy relies on and exploits the characteristics of malignant cells to attack tumors with radiation. Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer helps readers understand this exciting radiopharmaceutical field with up-to-date developments and step-by-step discussion covering a range of diverse topics, including optimization in the design of biomolecules and radiochemistry, cell and animal models for preclinical evaluation, discoveries from pivotal clinical trials, radiation biology and dosimetry, and considerations in regulatory approval. Unique aspects of the book include:* A translational focus on development, preclinical, and clinical evaluation of novel targeted radiopharmaceuticals for treating cancer* A discussion on health economics issues that have an impact on the ultimate use of targeted radiotherapy in clinical oncology* A broad discussion of the utility of targeted radiotherapy for multiple tumor types* New and emerging areas like molecular imaging, the bystander effect, and combining targeted radiotherapy with cytolytic virus therapy of tumorsMonoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer enlists internationally renowned experts and emerging leaders in the field who explain the groundbreaking science that has delivered a wealth of new findings and is defining the role of this new cancer treatment in the future. Review of the current state of the art provides provocative insight from today's cancer researchers as they reach for tomorrow's cures. Zusammenfassung Oncology Book of 2011, British Medical Association's Medical Book Awards Awarded first prize in the Oncology category at the 2011 BMA Medical Book Awards, Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer helps readers understand this hot pharmaceutical field with up-to-date developments. Inhaltsverzeichnis Preface. Contributors. 1. Antibody Engineering: Optimizing the Delivery Vehicle ( Diane E. Milenic ) . 1.1 Introduction. 1.2 Intact Murine Monoclonal Antibodies. 1.3 Recombinant Immunoglobulin Molecules. 1.4 Nanobodies. 1.5 Domain-Deleted Monoclonal Antibodies. 1.6 Hypervariable Domain Region Peptides. 1.7 Fv Fragments. 1.8 Minibodies. 1.9 Selective High Affinity Ligands. 1.10 Affibodies. 1.11 Other Strategies. 1.12 Concluding Remarks. References. 2. The Radiochemistry of Monoclonal Antibodies and Peptides ( Raymond M. Reilly ) . 2.1 Introduction. 2.2 Tumor and Normal Tissue Uptake of Monoclonal Antibodies and Peptides. 2.3 Selection of a Radionuclide for Tumor Imaging. 2.4 Selection of a Radionuclide for Targeted Radiotherapy. 2.5 Labeling Antibodies and Peptides with Radiohalogens. 2.6 Labeling Antibodies and Peptides with Radiometals. 2.7 Characterization of Radiolabeled mAbs and Peptides. 2.8 Summary. Acknowledgments. References. 3. The Design of Radiolabeled Peptides for Targeting Malignancies ( Leonard G. Luyt ) . 3.1 Introduction. 3.2 Peptide Targets. 3.3 Peptides as Cancer Targeting Agents. 3.4 Multimodality Agents. 3.5 Future Outlook. References. 4. Peptide Receptor Radionuclide Therapy in P...

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.